SELLAS Life Sciences says its Phase 3 REGAL trial of galinpepimut-S (GPS) for acute myeloid leukemia has reached its 80th event
MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.
MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.